Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: 09-12 Phase I Study of Platinum-based Chemoradiotherapy (CRT) with Oral Rigosertib in Patients with Intermediate or High-risk Head and Neck Squamous Cell Carcinoma

 


09-12 Phase I Study of Platinum-based Chemoradiotherapy (CRT) with Oral Rigosertib in Patients with Intermediate or High-risk Head and Neck Squamous Cell Carcinoma


Trial Focus

Head and Neck Cancers

Objective

         This is a clinical trial of Platinum-based Chemoradiotherapy (CRT) with Rigosertib which will be administered orally.

IRB Protocol #

13-2591

Trial Status

Archived

Principle Investigator

ANTONIO JIMENO

Sponsor

Onconova

Contact

EMILY WARNOCK at (720)848-0630 or EMILY.WARNOCK@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. The time to complete the screening tests can last up to 14 days. There will be 3 dose level groups. Subjects in the first dose group will be given the lowest dose of Oral Rigosertib combined with radiation and cisplatin. If no unacceptable side effects are seen in these subjects, the second group will be given the next higher dose of Oral Rigosertib combined with radiation and cisplatin treatments. If no unacceptable side effects are seen in the second group, the third group of subjects will be given the highest dose of Oral Rigosertib combined with the same level of radiation and cisplatin. // Eligibility criteria include but are not limited to 18 years or older with High-risk Head and Neck Squamous Cell Carcinoma.Eligibility criteria include but are not limited to 18 years or older with High-risk Head and Neck Squamous Cell Carcinoma.